PMGC Holdings Stock Price, News & Analysis
Why is ELAB Stock Up Today?
Company Description
PMGC Holdings (NASDAQ: elab) is a publicly traded biotechnology company in the Pharmaceutical Preparations sector. The company has a market capitalization of $1.9M, ranking #6,972 among all listed U.S. companies by market cap.
elab stock has declined 98.5% over the past year. Shares last traded at $5.99.
On a trailing twelve-month basis, PMGC Holdings reported revenue of $590K with net income of -$7.7M and diluted earnings per share of $-382.30. The company operates at a net profit margin of -1313.0%.
This page provides a comprehensive overview of elab stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
PMGC Holdings (elab) stock last traded at $5.99, up 19.37% from the previous close. Over the past 12 months, the stock has lost 98.5%. At a market capitalization of $1.9M, elab is classified as a micro-cap stock with approximately 1.2M shares outstanding.
Latest News
PMGC Holdings has 10 recent news articles, with the latest published yesterday. Of the recent coverage, 5 articles coincided with positive price movement and 5 with negative movement. Key topics include stock split, clinical trial, AI, acquisition. View all elab news →
SEC Filings
PMGC Holdings has filed 5 recent SEC filings, including 4 Form 8-K, 1 Form 10-K. The most recent filing was submitted on March 31, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all elab SEC filings →
Financial Highlights
PMGC Holdings generated $590K in revenue over the trailing twelve months, retaining a 31.4% gross margin, and net income was -$7.7M, reflecting a -1313.0% net profit margin. Diluted earnings per share stood at $-382.30. The company generated -$5.9M in operating cash flow.
Upcoming Events
Phase III results expected
PMGC Holdings has 1 upcoming scheduled event. The next event, "Phase III results expected", is scheduled for April 1, 2026 (today). Investors can track these dates to stay informed about potential catalysts that may affect the elab stock price.
Short Interest History
Short interest in PMGC Holdings (elab) currently stands at 33.1 thousand shares, down 61.9% from the previous reporting period, representing 6.1% of the float. Over the past 12 months, short interest has decreased by 73.1%.
Days to Cover History
Days to cover for PMGC Holdings (elab) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 2.8 days.
elab Company Profile & Sector Positioning
PMGC Holdings (elab) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.
Investors comparing elab often look at related companies in the same sector, including Scisparc (SPRC), Revelation Biosciences (REVB), Qualigen Therapeutics Inc (QLGN), Unity Btech (UBX), and Indaptus Therapeutics Inc (INDP). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate elab's relative position within its industry.
AGA Precision Systems (NASDAQ: ELAB), an aerospace and defense components supplier, said onMar 31 it signed a 5-year long-term agreement with Turbo-Jet Products to supply mission-critical parts for regulated U.S. defense programs.
The company reported AS9100 certification and ITAR compliance as part of the deal.